カレントテラピー　35-2　サンプル page 27/32

このページは カレントテラピー　35-2　サンプル の電子ブックに掲載されている27ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　35-2　サンプル

Current Therapy 2017 Vol.35 No.2 81治療薬解説179kinase in Treg cells maintains homeostasis and lineage stability.Nat Immunol 16：188-196, 201514）Hu-Lieskovan S, Mok S, Homet Moreno B, et al：Improvedantitumor activity of immunotherapy with BRAF and MEKinhibitors in BRAF（V600E）melanoma. Sci Transl Med 7：279ra41, 201515）Matsubara Y, Hori T, Morita R, et al：Phenotypic and functionalrelationship between adult T-cell leukemia cells andregulatory T cells. Leukemia 19：482-483, 200516）Chen S, Ishii N, Ine S, et al：Regulatory T cell-like activityof Foxp3＋ adult T cell leukemia cells. Int Immunol 18：269-277, 200617）Shimazu Y, Shimazu Y, Hishizawa M, et al：Hypomethylationof the Treg-Specific Demethylated Region in FOXP3 Is aHallmark of the Regulatory T-cell Subtype in Adult T-cellLeukemia. Cancer Immunol Res 4：136-145, 201618）Rech AJ, Mick R, Martin S, et al：CD25 blockade depletesand selectively reprograms regulatory T cells in concertwith immunotherapy in cancer patients. Sci Transl Med 4：134ra62, 201219）Takeuchi Y, Nishikawa H：Roles of regulatory T cells in cancerimmunity. Int Immunol 28：401-409, 201620）Sugiyama D, Nishikawa H, Maeda Y, et al：Anti-CCR4 mAbselectively depletes effector-type FoxP3＋CD4＋ regulatoryT cells, evoking antitumor immune responses in humans.Proc Natl Acad Sci U S A 110：17945-17950, 201321）Ishida T, Joh T, Uike N, et al：Defucosylated anti -CCR4monoclonal antibody（KW-0761）for relapsed adult T-cellleukemia -lymphoma：a multicenter phaseⅡstudy. J ClinOncol 30：837-842, 201222）Kurose K, Ohue Y, Wada H, et al：Phase Ia Study of FoxP3＋CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4Antibody, KW -0761, in Cancer Patients. Clin Cancer Res21：4327-4336, 201523）Brahmer J, Reckamp KL, Baas P, et al：Nivolumab versusDocetaxel in Advanced Squamous -Cell Non -Small -CellLung Cancer. N Engl J Med 373：123-135, 201524）Borghaei H, Paz-Ares L, Horn L, et al：Nivolumab versusDocetaxel in Advanced Nonsquamous Non-Small-Cell LungCancer. N Engl J Med 373：1627-1639, 201525）Motzer RJ, Escudier B, McDermott DF, et al；CheckMate025 Investigators：Nivolumab versus Everolimus in AdvancedRenal-Cell Carcinoma. N Engl J Med 373：1803-1813, 201526）Hamanishi J, Mandai M, Ikeda T, et al：Safety and AntitumorActivity of Anti-PD-1 Antibody, Nivolumab, in Patients WithPlatinum-Resistant Ovarian Cancer. J Clin Oncol 33：4015-4022, 201527）Tumeh PC, Harview CL, Yearley JH, et al：PD-1 blockadeinduces responses by inhibiting adaptive immune resistance.Nature 515：568-571, 201428）Corrales L, Glickman LH, McWhirter SM, et al：DirectActivation of STING in the Tumor Microenvironment Leadsto Potent and Systemic Tumor Regression and Immunity.Cell Rep 11：1018-1030, 201529）Spranger S, Bao R, Gajewski TF：Melanoma -intrinsic β-catenin signalling prevents anti-tumour immunity. Nature523：231-235, 2015